Pharmacodynamics of progesterone women, this effect being the result of suppression of the mid-cycle surge in gonadotropin secretion, is 300 mg/day. However, this figure is based on limited clinical data. Conversely, treatment with a high dosage of oral progesterone of 100 mg four times per day (or 400 mg/day total) in men for 10 days that resulted in approximately mid-luteal phase levels of progesterone (7.9–9.4 ng/mL; measured by ) did not cause any change in testosterone levels, suggesting that progesterone has little or no antigonadotropic effect in males at typical clinical dosages. In addition, a study found that administration of 1,000 mg/day oral
Topical progesterone of tissue exposure to progesterone with this route of administration. These findings provide a possible explanation for how some studies found antiproliferative and atrophic changes in the endometrium with topical progesterone. However, elevated levels of progesterone in the endometrium with topical progesterone have not yet been demonstrated. Concern has been raised regarding topical progesterone in that the effects of such supraphysiological levels of progesterone in tissues are unknown and hence the potential for harmful effects has not been ruled out. Salivary monitoring of progesterone levels in women using topical progesterone and adjustment of dosage as necessary has been suggested as